Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01547546 · ClinicalTrials.gov registry record · Phase 1
A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma
A Phase 1 study of Glioblastoma, Glioma, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 5
- Study locations
NCT01547546 is a Phase 1 study of Glioblastoma, Glioma that has completed, run by Genentech. The registered enrollment target is 29 participants. The trial reports 5 study locations across 4 states.
The verdict
NCT01547546, a Phase 1 study of Glioblastoma, Glioma, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 5
- Study locations
Study Summary
This open-label, multicenter, Phase I, dose-escalating study will evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics and efficacy of GDC-0084 in patients with progressive or recurrent high-grade glioma. Stage 1 is the dose escalation part of the study. Stage 2, patients will receive GDC-0084 at a recommended dose for future studies.
Conditions Studied
Interventions
- DRUG GDC-0084
Study Locations (5)
Massachusetts
- - Boston
- - Boston
California
- - Los Angeles
Texas
- - Houston
Barcelona
- - Barcelona
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2012-04 |
| Est. Completion | 2015-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01547546
The ClinicalTrials.gov registry entry for NCT01547546 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma, Glioma appearing as the primary indexed condition, and to 1 intervention - of which GDC-0084 is the first listed.
NCT01547546 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Massachusetts, California, Texas.
Frequently Asked Questions
What is clinical trial NCT01547546 about?
NCT01547546 is a clinical study titled "A Study of GDC-0084 in Patients With Progressive or Recurrent High-Grade Glioma". This open-label, multicenter, Phase I, dose-escalating study will evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics and efficacy of GDC-0084 in patients with progressive or recurrent high-grade glioma. Stage 1 is the dose escalation part of the study. Stage 2, patients will re...
What is the current status of trial NCT01547546?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2012-04. Estimated completion is 2015-01.
What conditions does trial NCT01547546 study?
This clinical trial studies the following conditions: Glioblastoma, Glioma.
What interventions are being tested in trial NCT01547546?
The interventions under investigation include: GDC-0084 (DRUG).
Who is sponsoring clinical trial NCT01547546?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01547546 being conducted?
This trial has 5 study locations across California, Massachusetts, Texas, Barcelona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.